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Objective: Pro-inflammatory cytokine-driven mechanisms have been implicated in vein graft failure, though little is known
about the effect of hemodynamic factors and anti-inflammatory counter-regulatory mechanisms. We hypothesized that
early temporal expression of the pro-inflammatory cytokine interleukin (IL)–1 and the anti-inflammatory cytokine
IL-10 proceeds by way of wall shear stress–dependent pathways in the arterializing vein graft.
Methods: Rabbits (n 27) underwent bilateral jugular vein carotid interposition grafts, and simultaneous unilateral distal
carotid branch ligation, to produce both low-flow and high-flow grafts in the same animal. Vein grafts were harvested at
1, 3, 7, 14, and 28 days and were assessed for architecture, wall shear stress, and cytokine messenger RNA levels
(quantitative real-time two-step reverse transcription polymerase chain reaction).
Results: The model resulted in an immediate 90% flow reduction (P < .001, paired t test) in the vein graft on the ligated
side, and a 36% increase (P .01) in contralateral graft flow. This persisted as15-fold flow differential throughout the
28-day period. The construction yielded a 15-fold differential in wall shear stress between low-flow and high-flow vein
grafts (P < .001, two-way repeated measures analysis of variance). Intimal hyperplasia began by day 3, and was 6-fold
more in low wall shear grafts by 28 days (230.6 35.4 m intimal thickness vs 36.1 17.6 m for low shear versus high
shear grafts; P  .001). For both cytokines time independently affected mRNA expression (P < .001, global analysis of
variance). Exposure of vein grafts to the arterial circulation markedly up-regulated IL-1 at 1 day, with significantly more
induction in the low shear setting (P  .002). IL-1 protein localized to the developing neointima at days 1 and 3.
Conversely, IL-10 slowly increased until day 14, with significantly more expression in the high shear grafts (P < .001).
Conclusions: Vein graft adaptation induces early pro-inflammatory cytokine IL-1 expression and delayed protective
IL-10 expression (most notable under high shear conditions), both of which are modulated by wall shear. These
differential temporal windows offer strategies for appropriately timed pro-inflammatory or anti-inflammatory therapies
to interrupt pathologic vein graft adaptations. (J Vasc Surg 2004;40:345-50.)
Clinical Relevance: Neointimal hyperplasia continues to limit the durability of vein bypass grafts. Emerging evidence
suggests that inflammatory mechanisms drive the neointimal hyperplasic response. This study demonstrates that specific
hemodynamic forces (altered wall shear stress) differentially affect early pro-inflammatory interleukin (IL)–1 and
delayed anti-inflammatory IL-10 signaling. These distinct temporal windows for IL-1 and IL-10 cytokine expression
offer strategies for appropriately timed pro-inflammatory and anti-inflammatory therapies to interrupt pathologic vein
graft adaptations.Use of autologous vein bypass grafts is the most durable
standard for revascularization procedures performed to
treat occlusive cardiovascular diseases. In the United States
it is estimated that 571,000 coronary artery bypass proce-
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procedures were performed in 1999. However, almost 20%
of these vein bypass grafts will fail within a year, and 40%
will fail by 5 years.2,3 Vein grafts undergo a defined se-
quence of adaptations after arterialization, though not all
favor long-term patency. Although pathologic hallmarks of
intimal hyperplasia have been well described, few substan-
tial clinical interventions to prolong bypass graft patency
have been found. Since many technical avenues for im-
proved patency have been exhausted over recent decades,
the future of improving the durability of these construc-
tions lies primarily in better knowledge of and interventions
based on the biologic features of the vein graft wall.
Inflammation is a pathologic feature of vein graft arte-
rialization and failure, though it remains unclear whether
the inflammation is primary or secondary. Pro-inflammatory
cytokines tumor necrosis factor (TNF)– and interleukin
(IL)–1, have been associated with vein graft arterialization
and intimal hyperplasia4,5; however, the initiating factors345
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these inflammatory mediators in vein wall adaptations re-
main largely unknown. In addition, while both low and
high wall shear environments induce arterial wall pro-
inflammatory cytokines,6-9 the relationship between hemo-
dynamics and vein graft cytokine signaling is not under-
stood.
Thus we sought to determine the temporal expression
of the pro-inflammatory cytokine IL-1 and the anti-
inflammatory cytokine IL-10 in response to specific early
vein graft hemodynamic circumstances, that is, high and
low wall shear stress. We hypothesized that the low wall
shear stress hemodynamic setting, which exacerbates occlu-
sive intimal hyperplasia, induces IL-1 expression, whereas
high shear induces IL-10, and that both are time-depen-
dent.
METHODS
Rabbit model of high and low wall shear vein
grafts. This study was performed after securing appropri-
ate institutional approval, and conforms with the Guide for
the Care and Use of Laboratory Animals (National Insti-
tutes of Health Publ No. 85-23, revised 1996). Twenty-
seven male New Zealand White rabbits (3.0-3.5 kg) under-
went bilateral jugular vein interposition grafting followed
by immediate unilateral distal carotid artery branch liga-
tion, to create defined regions of differential vein graft wall
shear.10 Rabbits were premedicated with ketamine (30
mg/kg intramuscularly), endotracheal tubes were placed,
and the animals were anesthetized with isoflurane. Intrave-
nous heparin (1000 U) was administered, and bilateral
external jugular veins and common carotid arteries were
exposed through a vertical midline cervical incision. Vein
bypass grafts were constructed with an anastomotic cuff
technique, as described.10 In brief, bilateral external jugular
veins (3-cm long) were harvested. Polymer cuffs consisting
of a 1-mm body loop were fashioned from a 4F endovas-
cular catheter (Terumo Medical Corporation). Jugular vein
ends were passed through a cuff, everted, and fixed with 8-0
silk suture. The carotid artery lumen was then exposed
through a 2-cm arteriotomy, and the cuffed, reversed vein
ends were inserted. A second 8-0 silk suture was used to
secure the artery around the cuff. Finally, 1.0 cm of carotid
artery back wall between the cuffs was cut away to permit
vein graft extension.
Unilateral reduction in carotid artery, and thus vein
graft, flow was accomplished with placement of 8-0 silk
suture ligatures to completely occlude the internal carotid
artery and three of the four primary branches of the external
carotid artery. Mean blood flow rate through the arteries
Cytokine primers and probes for quantitative real-time two
Gene Forward primer Rever
IL-1 TTGCTGAGCCAGCCTCTCTT CTGGGTACCAA
IL-10 TGCGACAATGTCACCGATTT TGCTGAAGGCGwas recorded with an ultrasonic flow meter (2.0-mm probe;
T106, Transonic Systems), both before and after ligation of
the distal arterial branches. Animals (n  5 for each time
point) were euthanized at 1, 3, 7, 14, and 28 days. Four
normal, unmanipulated jugular veins were harvested from
separate animals, and served as time zero baseline controls.
Graft flow rates were recorded at harvest, again with use of
the ultrasonic flow meter. High-resolution video images
were obtained both at graft placement and harvest, and
were used to determine external graft dimensions. Speci-
mens were frozen in liquid nitrogen or immediately im-
mersed in 10% neutral buffered formalin, avoiding the
tissue within 2.0 mm adjacent to either cuff.
Morphologic analysis and hemodynamics. Morpho-
logic analyses were completed with both in vivo external
graft diameter and cross-sectional measurements (Axio-
vision v 3.1; Zeiss) on Masson and van Gieson elastin-
stained specimens. Digitized in vivo digital video and fixed
microscopic cross-sectional images were collected and an-
alyzed to determine lumen diameter (DV) and neointimal
cross-sectional area for each specimen. Wall shear stress was
calculated from   32 Q/DV
3, where Q is mean flow
rate and  is viscosity (0.03 poise).
Cytokine expression. Quantitative real-time two-
step reverse transcription polymerase chain reaction (RT-
PCR) was performed on paired vein grafts collected from all
animals. Total RNA was isolated with TRI and BCP phase
separation reagents according to the manufacturer’s proto-
col (Molecular Research Center). After treatment with
deoxyribonuclease I (Ambion), reverse transcription was
completed with random hexamers (PE Applied Biosystem)
to obtain a final complementary DNA concentration of 20
ng/L. TaqMan RT-PCR for IL-1 and IL-10 (Table)
was performed on a PE 7700 Sequence Detection System,
with use of 200 nmol/L forward primer, 200 nmol/L
reverse primer, 50 nmol/L probe, and 10 ng cDNA per 25
L reaction volume (TaqMan Universal PCR Master Mix;
PE Applied Biosystems). RT-PCR was run for 18S ribo-
somal RNA on all cDNA samples as an internal control.
Samples were assayed in triplicate. The Comparative CT
method11 was used for experiments and data analysis. Re-
sults were expressed as relative IL-1 or IL-10 mRNA
expression after normalization to 18S ribosomal RNA to
minimize variability from RNA quality and RT efficiency,
and finally were calibrated to unmanipulated jugular vein.
Immunohistochemical analysis. For IL-1 cytokine
immunohistochemistry, tissues were fixed in 4% formalin,
dehydrated, and embedded in paraffin, and 4-m thick
sections were made. The slides were rehydrated, treated
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nol. Sections were washed with Tris-buffered saline solu-
tion (TBS) and blocked with 10% normal rabbit serum for
1 hour at room temperature. Staining for IL-1was carried
out with affinity purified goat anti-rabbit IL-1 immuno-
globulin G (IgG) as a primary antibody (5 g/mL in
TBS-1% bovine serum albumin for 2 hours at 37°C). Pre-
immune goat IgG was used as control, as was unmanipu-
lated vein.12 After washing with TBS–Tween 20 (0.1%),
the slides were incubated with rabbit anti-goat IgG conju-
gated to horseradish peroxidase–labeled dextran polymer
(EnVision Plus Peroxidase; Dako Cytomation) for 30 min-
utes at room temperature. After washing, the reaction was
developed with diaminobenzidine (Sigma). Counterstain-
ing was performed with hematoxylin.
Statistical analysis. The role of time and wall shear
was described statistically with two-way repeated measures
analysis of variance, Wilcoxon signed rank test, and paired t
tests. When possible, pairwise analyses were performed.
Multiple comparisons were completed with the Student-
Newman-Keuls method (Sigma Stat; SSPS).
RESULTS
Rabbit model of high and low wall shear vein
grafts. The surgical, physiologic, and biomechanical out-
comes of this model have been described.10 Significant
surgical morbidity and mortality were zero. In brief, distal
branch ligation resulted in an immediate 90% flow reduc-
tion (P .001) in the vein graft on the ligated side and 36%
flow augmentation (P .01) in the contralateral vein graft.
Associated with this flow perturbation was an approximate
15-fold differential flow rate detected in vein grafts
throughout the 28-day observation period. The shear force
differed 15-fold initially between low-flow and high-flow
vein grafts. While no significant alteration in shear stress
was detectable in low- flow grafts over time, a late 68%
decrease (P  .039) of shear stress occurred by day 28 in
Fig 1. Examples of low (A) and high (B) wall shear vein
(C).high-flow vein grafts, owing to outward vein wall
remodeling.
Morphologic features. As detailed previously,10 neo-
intimal hyperplasia was first noted at day 3 in both low-flow
s (28 days; Masson trichrome), and normal jugular vein
Fig 2. Relative messenger RNA expression calibrated to normal
vein. Results are expressed as relative interleukin-1 or interleu-
kin-10 mRNA expression after normalization to 18S ribosomal
RNA, to minimize variability from RNA quality and RT efficiency,
and finally calibrated to unmanipulated jugular vein. With arteri-
alization, vein wall interleukin-1 exhibits rapid induction that is
higher in the low shear stress setting. On the other hand, interleu-
kin-10 exhibits relatively delayed upregulation, most notably by
high wall shear stress at 14 days.graft
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hyperplasia was observed in low-flow shear grafts between
day 7 (42.4 	 14.5 m) and day 14 (181.4 	 31.1 m),
averaging 230.6 	 35.4 m by day 28. In the high-flow
shear grafts, however, marked reduction in neointimal hy-
perplasia (P  .001) was seen, with intimal thickness ap-
proximately one sixth that in low-flow grafts at day 28
(36.1	 17.6 m; Fig 1). Serial sections from the proximal,
middle, and distal portions of perfusion-fixed vein grafts
showed no consistent variation in extent of intimal
thickening.10
Cytokine expression quantitation. RT-PCR for
IL-1 and IL-10 revealed several shear and time-depen-
dent cytokine expression signatures (Fig 2). Time after vein
graft arterialization was a statistically significant overall
determinant of expression for both cytokines (P .001 for
each).
IL-1 was induced 1188-fold in low shear vein grafts
and 366-fold in high shear vein grafts by the first post-
arterialization day. This elevation was followed by a rapid
reduction toward baseline by the third day. Flow signifi-
cantly affected IL-1 expression (P  .001), though the
differential was greatest at 1 day (P .002) and 3 days (P
.001).
On the other hand, vein graft arterialization more
slowly and modestly induced IL-10 mRNA expression.
Overall, this occurred independent of shear (P  .152),
though there was a statistically significant higher expression
for high shear grafts at 14 days (P  .001).
Immunohistochemical analysis. IL-1 stained in-
tensely, and localized to the developing neointima at days 1
and 3 (Fig 3). IL-10 studies were not performed, because
of lack of appropriate anti-rabbit IL-10 antibodies.
DISCUSSION
Vein grafts undergo a defined sequence of adaptations
after arterialization, though not all favor long-term pa-
tency. Their failure mechanisms seem to generally mirror
Fig 3. Interleukin-1 localized to developing neointima
demonstrates negative staining.the occlusive disease seen in arteries. If the hemodynamic
environment that led to this adaptation of the vein graft
wall is removed and the vein is placed back into the venous
system, the structure of the vein wall reverts toward its
original architecture.4 This strongly implicates hemody-
namic factors as the determinant of vein graft adaptations.
Research during the 1980s and 1990s yielded impor-
tant new knowledge regarding the mechanisms of vein graft
failure. Early work focused on mechanical factors.13-16
Intimal hyperplasia has been noted to occur at vein graft
areas of low flow,13 probably areas of low wall shear
stress.14,15 Progress has been made in deciphering the
biochemical mediators of the cellular events induced by
these hemodynamic forces,17-19 and the rabbit vein graft
model facilitated much of this research.19-21
More recent work has specifically examined the role of
inflammatory mediators in vein graft failure.4,5,22-24 With
use of previous technologies, perturbations in cytokine and
growth factor levels have been associated with vein graft
arterialization,4,22,25 but specific cause-and-effect links be-
tween hemodynamic factors, inflammatory biochemical
mediators, and vein wall adaptations are still lacking.
Since these initial studies, more powerful molecular
techniques and enhanced therapeutic approaches have
been developed. It is in this setting that we sought to build
on this previous work, to more precisely define the tempo-
ral expression of prototypical cytokines IL-1 and IL-10 in
response to specific early vein graft hemodynamic circum-
stances (high and low wall shear stress). Our results reveal
striking time-dependent perturbations and shear modula-
tion of mRNA expression patterns for these cytokines.
In our previously described model, low shear grafts
develop robust intimal hyperplasia.10 In contrast, high
shear triggers mechanisms that appear to protect against
occlusive adaptations. Thus we examined vein grafts in
these differential flow environments (relatively labeled low
and high shear) in the same animal, which enabled more
powerful statistical analysis. Vein grafts are exposed to the
s after vein graft placement. Unmanipulated control vein3 day
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“normal” shear for human vein grafts, though our model
captures clinically relevant ranges from 2 to 20 dynes/cm2.
Directed attention across this spectrum enables us to sys-
tematically link shear stress forces with specific cytokine
signaling pathways.
Experimental studies have documented direct evidence
of IL-1 participation in the modulation of arterial intimal
growth, and lack of biologically active IL-1 abrogates
arterial intimal hyperplasia.7 Locally chronic delivery of
IL-1 to coronary adventitia induced neointima formation,
and this effect is abolished by simultaneous treatment with
neutralizing antibody to IL-1.26 In vitro studies demon-
strate that IL-1 holds many properties that suggest its
involvement in vein graft failure. It induces adhesion mol-
ecule expression,27 alters endothelial cell surface in a man-
ner that favors coagulation and thrombosis, acts as a che-
moattractant to monocytes and macrophages, and
stimulates smooth muscle cell migration and prolifera-
tion.28 Experiments performed on the balloon-injured por-
cine coronary artery demonstrated very early and short (first
3 days) IL-1mRNA expression in injured artery.29 Under
the condition of our experiments, most IL-1 produced
locally in the arterializing vein graft occurs in the first few
days, and this matches the protein-based determinations of
others,5 as well as the arterial wall response.29 IL-1 pro-
tein localized to the developing neointima at early time
points, which confirmed the expression data. With such a
narrow early time window, there is potential for enormous
effect from a properly timed short course of anti-IL-1
therapy to minimize longer term vein graft occlusive adap-
tations. Such an approach might be accomplished with
drugs already available for clinical use, such as anakinra.30
Consistent with the theory that pro-inflammatory cy-
tokine mechanisms drive downstream vein graft adapta-
tions, this early quantitative IL-1 mRNA level change is
temporally distinct from the time course of later morpho-
logic and cellular changes in the vein graft wall. High
pro-inflammatory cytokine levels, as in the low flow setting,
correlated positively with greater intimal hyperplasia.
As opposed to IL-1, induction of IL-10 by vein graft
arterialization occurred slowly, reaching a peak 2 weeks
later. The significantly higher IL-10 levels induced by the
high shear setting, which also protected against occlusive
wall changes, supports a protective effect for IL-10. Early
administration of IL-10 may provide a useful strategy for
early inflammation suppression.31 Our findings provide
new direct in vivo evidence for IL-10 signaling in vein graft
arterialization.
There are limitations to our study that prevent broader
conclusions. While we probably accurately interrogated the
mRNA expression in these whole tissues, limited informa-
tion is provided regarding actual active protein levels and
exact localization, especially for IL-10, because we were
unable to confirm the mRNA expression due to lack of
appropriate antibodies. Thus it must be acknowledged that
there could be post-transcriptional regulation or other
disconnects between transcription and translation that mayaffect the final active protein levels in this system. Cytokine
receptor dynamics may also serve as an important control
point for modulation of these inflammatory processes.
Understanding the molecular mechanisms of vein graft
failure will suggest clinical interventions that will alter the
natural history of the process. The early IL-1–mediated
and IL-10–mediated processes serve as a potential early site
for therapeutically interrupting pathologic vein graft adap-
tations to arterialization.32-35 The dramatic differences in
neointimal burden between high and low shear stress grafts
in this model suggest that modest perturbations in cytokine
activities may substantially affect early vein graft remodel-
ing.
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